Clinical trial · Interventional
Monitoring of Neurological Symptoms, Treatment Tolerance, and Quality of Life Using the Resilience PRO Electronic Patient-reported Outcome Application in Patients With IDH-mutated Glioma
A Prospective Multi-center Study to Monitor Neurological Symptoms, Treatment Tolerance, and Quality of Life Using the Resilience PRO Electronic Patient-reported Outcome Application in Patients With IDH-mutated Glioma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with IDH-mutant glioma frequently experience symptoms such as fatigue, seizures, headaches, cognitive impairments (primarily attentional), and mood changes, which can significantly affect their health-related quality of life (HRQoL). Disease progression and treatment-related toxicities are the two primary factors driving the decline in HRQoL in this population. These symptoms can be exacerbated by side effects from available therapeutic options, such as chemotherapy, radiation therapy, or targeted IDH inhibitors. In this context, it is crucial to consider the combined effects of these treatments on patient symptoms and HRQoL. Given that this population is young and otherwise healthy, with long-term survival exceeding 10 years after diagnosis, it is essential to consider not only on longevity but also on overall functioning and HRQoL when making treatment decisions. Assessing quality of life has therefore become a key parameter in phase III clinical trials and observational studies under real-world conditions. The Resilience PRO digital medical device (DMD; CE-marked class IIa) enables remote monitoring of patients treated for cancer who are receiving systemic therapy. Resilience PRO has been positively evaluated by the French National Health Authority (HAS) and included on the LATM list under its brand name. Resilience PRO sends validated weekly questionnaires to patients (NCI PRO-CTCAE ePatient Reported Outcomes \[ePROs\]), inquiring about treatment- and disease-related symptomatic adverse events. The associated alert algorithm, equivalent to those used in the STAR and PRO-TECT studies, allows for the proactive management of severe or worsening symptoms by the healthcare professional receiving the alert. Additionally, Resilience PRO provides patients with personalized access to a mobile app that offers resources aimed at improving education, self-management, and patient engagement. These innovations lead to clinical benefits (improved quality of life, reduced morbidity, and increased overall survival), as well as organizational benefits (reduced emergency room visits and hospitalizations) and economic advantages.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
| Oncology | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neurocognitive assessment | Behavioral | — | UNRESOLVED |
| Questionnaries QoL | Other | — | UNRESOLVED |
| Resilience Pro Application | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental Arm
- description
- Neurocognitive assessment and quality of life using Résilience Pro app
- interventionNames
- Behavioral: Neurocognitive assessment
- Other: Questionnaries QoL
- Device: Resilience Pro Application
Primary outcomes (1)
- measure
- The primary objective of the study is to assess the quality of life using the QLQ-C30 questionnaire in IDH-mutant gliomas patients in real-world conditions treated with systemic treatment (IDH inhibitor, PCV, TMZ).
- timeFrame
- 12 months
- description
- QOL scores will be followed every two weeks using the Resilience PRO tool. QOL global score deterioration will be defined as a deterioration with a minimal clinically important difference ≥ 10 points as compared to the baseline score (V1 - M0) . Baseline score evaluation will be performed before the initiation of systemic therapy. Proportion of patient with a QoL score deterioration will be reported at clinically relevant timepoints such as 6 and 12 months.
Secondary outcomes (7)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adults (over 18 years of age) 2. Written consent from the patient to participate in the clinical study 3. Diagnosed with grade 2-4 glioma with IDH1/2 mutation 4. Plan to initiate new systemic treatment for glioma (chemotherapy, targeted therapy, or other investigational antitumor systemic agent) 5. Candidate for ePRO monitoring using Resilience PRO medical device according to local investigator decision 6. Social security coverage Exclusion Criteria: 1. Severe language impairment 2. Cognitive deficit preventing the understanding of essential elements for questionnaires 3. Patient under guardianship or curatorship
References
Publications (0)
Data not yet available